multicent trial ursodiol treatment primari biliari cirrhosi udca-pbc studi group background primari biliari cirrhosi hepat lesion part intracellular accumul toxic endogen bile acid preliminari work administr ursodiol ursodeoxychol acid hydrophil bile acid hepatotox improv condit patient primari biliari cirrhosi method two-year multicent double-blind trial efficaci ursodiol placebo patient biopsy-prov primari biliari cirrhosi ursodiol mg kilogram bodi weight day placebo treatment failur doubl bilirubin level mumol liter occurr sever complic advers reaction result treatment patient ursodiol group placebo group cox regress model singl patient group minor advers effect year treatment proport patient overt diseas ursodiol group patient ursodiol signific improv serum level bilirubin alkalin phosphatas alanin aminotransferas aspart aminotransferas gamma-glutamyltransferas cholesterol igm antimitochondrial-antibodi titer mayo risk score follow-up analysi liver-biopsi specimen signific improv mean histolog score characterist histolog featur fibrosi group conclus ursodiol safe effect treatment primari biliari cirrhosi 